Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Recruiting now · Phase 2
Conditions studied: Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis, Alport Syndrome
In brief
To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.
Key facts
- Study ID
- NCT05003986
- Run by
- Travere Therapeutics, Inc.
- People needed
- 67
- Starts
- 2021-08-12
- Expected to finish
- 2027-04-12
- Last updated by the study team
- 2026-05-12
Who can join
Age: 1 and older, up to 17. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Manchester University NHS Foundation Trust — Manchester, United Kingdom (enrolling)
- Nemours Children's Hospital — Wilmington, Delaware, United States (enrolling)
- University of Miami, Leonard M. Miller School of Medicine — Miami, Florida, United States (enrolling)
- Nicklaus Children's Hospital — Miami, Florida, United States (enrolling)
- Hospital Universitario La Paz — Madrid, Spain (enrolling)
- Hospital Universitario Virgen del Rocío — Seville, Spain (enrolling)
- Drottning Silvias Barn- och Ungdomssjukhus — Gothenburg, Sweden (enrolling)
- Karolinska Universitetssjukhuset Huddinge — Stockholm, Sweden (enrolling)
- University Hospitals Bristol and Weston NHS Foundation Trust, Bristol Royal Hospital for Children — Bristol, United Kingdom (enrolling)
- NHS Greater Glasgow and Clyde, Royal Hospital for Children — Glasgow, United Kingdom (enrolling)
- Alder Hey Children's NHS Foundation Trust — Liverpool, United Kingdom (enrolling)
- Great Ormond Street Hospital for Children NHS Foundation Trust — London, United Kingdom (enrolling)
- Cedars-Sinai Medical Center — Los Angeles, California, United States (enrolling)
- C.S. Mott Children's Hospital — Ann Arbor, Michigan, United States (enrolling)
- University of Minnesota, Masonic Children's Hospital — Minneapolis, Minnesota, United States (enrolling)
- Children's Mercy Hospitals and Clinics — Kansas City, Missouri, United States (enrolling)
- Hackensack University Medical Center — Hackensack, New Jersey, United States (enrolling)
- Jersey Shore University Medical Center — Neptune City, New Jersey, United States (enrolling)
- Cohen Children's Medical Center — New Hyde Park, New York, United States (enrolling)
- University of North Carolina at Chapel Hill — Chapel Hill, North Carolina, United States (enrolling)
- Duke Molecular Physiology Institute — Durham, North Carolina, United States (enrolling)
- Nationwide Children's Hospital — Columbus, Ohio, United States (enrolling)
- University of Oklahoma Health Sciences Center (OUHSC) — Oklahoma City, Oklahoma, United States (enrolling)
- Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States (enrolling)
- Texas Children's Hospital — Houston, Texas, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.